The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis ; day:18 ; month:3 ; year:2024 ; pages:1-9
Annals of hematology ; (18.3.2024), 1-9
- Creator
-
Wang, Zerong
Jin, Xuelian
Zeng, Jiajia
Xiong, Zilin
Chen, Xinchuan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00277-024-05703-1
- URN
-
urn:nbn:de:101:1-2405210729022.432736756252
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wang, Zerong
- Jin, Xuelian
- Zeng, Jiajia
- Xiong, Zilin
- Chen, Xinchuan
- SpringerLink (Online service)
Other Objects (12)
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation
Importance of allogeneic stem cell transplantation in myelofibrosis
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study
Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation
Importance of allogeneic stem cell transplantation in myelofibrosis
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study
Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation
Importance of allogeneic stem cell transplantation in myelofibrosis
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study
Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry